News Dupixent works in hard-to-treat form of atopic dermatitis IL-4 inhibitor shows its worth in atopic hand-foot dermatitis unresponsive to corticosteroids.
News Sanofi cuts price of Lantus insulin in US by 78% Pharma joins Eli Lilly, Novo Nordisk as it slashes the price of its widely-prescribed insulins.
News Sanofi buys Provention and diabetes drug Tzield for $2.9bn T1D prevention drug has been tipped as a blockbuster, boosting Sanofi's diabetes franchise.
News Sanofi sings a song for rare disease and equitable care 'This is Rare' campaign sings the plight of the rare disease community this awareness day.
News Sanofi boosts ‘connected insulin’ push with Glooko deal The alliance will pair Glooko's digital health platform with Sanofi's SoloSmart insulin device.
News Sanofi gets FDA nod for long-acting haemophilia A drug Once-weekly Altuviiio could be potential $2 billion-plus blockbuster, according to analysts.
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
